Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus preoperative radiotherapy for resectable undifferentiated pleomorphic sarcoma
ChiCTR1900027356Phase 2Recruiting
- Sponsor
- Zhengzhou University
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in Malignant Fibrous Histiocytoma (MFH) (2 arms), sponsored by Zhengzhou University. Primary endpoint: Pathologic response. Started Nov 2019; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Malignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on ChiCTR1900027356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027356.